vitaminNot FDA-approvedOTC supplementBenfotiamine is sold OTC as a dietary supplement in the US and is not FDA-approved as a drug for diabetic neuropathy or Alzheimer's diseaseThe Alzheimer's indication remains investigational; a larger phase 2A/2B trial (BenfoTeam) was registered to further test safety and efficacy
BenfotiamineBenefits, Dosage & Interactions
Also known as: Lipid-soluble B1
Benfotiamine is a synthetic, lipid-soluble derivative of thiamine (Vitamin B1). As a pro-drug, it is converted into thiamine within the body. Research on Benfotiamine focuses on heart and circulatory health and cognition and mood. It is typically taken with a meal.
How much Benfotiamine do people take?
600 mg per day was used in the pilot diabetic polyneuropathy trial; 300 mg per day was used in the phase IIa Alzheimer's trial. Route reported: Oral, given as tablets in both cited randomized trials. Frequency reported: Divided daily dosing (e.g., three times daily in the neuropathy pilot trial). These are amounts documented in the cited studies and labels for Benfotiamine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 2 human randomized trials published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials published.
Is benfotiamine simply another name for thiamine?
Benfotiamine is a thiamine derivative, not identical to ordinary vitamin B1 supplements. Different absorption does not itself prove better outcomes for nerve symptoms, kidney disease, or diabetes.
Source: Randomized benfotiamine nephropathy trial
Browse compound evidence cardsWhole-body biological half-life
Not applicable
Typical timing
with a meal
Food rule
with food
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Benfotiamine in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Benfotiamine entry is written from. Each number matches an inline marker above.
- [1]Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).Haupt E, Ledermann H, Köpcke W · International Journal of Clinical Pharmacology and Therapeutics · 2005 · Peer-reviewed · PMID 15726875
- [2]Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.Gibson GE, Luchsinger JA, Cirio R, Chen H, Franchino-Elder J, Hirsch JA · Journal of Alzheimer's Disease · 2020 · Peer-reviewed · PMID 33074237
- [3]Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam).Feldman HH, Luchsinger JA, Léger GC, Taylor C, Jacobs DM, Salmon DP · PLoS One · 2024 · Peer-reviewed · PMID 38809849
References & Evidence
Sources on this page that document Benfotiamine dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Benfotiamine studied for?
Deficiency-driven — not a performance booster
Vitamins primarily help when you're actually low. Extra doses on top of normal levels rarely add strength, endurance, or fat loss, and some fat-soluble vitamins (A, D, E, K) can build up to harmful levels.
- Confirm a deficiency with bloodwork before supplementing long-term (e.g. 25(OH)D for vitamin D, B12/folate, ferritin, magnesium RBC).
- Talk to your doctor or a registered dietitian about the right dose for your labs, medications, and conditions — especially in pregnancy, kidney/liver disease, or while on blood thinners.
- Re-test every 3–6 months and stop or lower the dose once levels are in range.
Educational information only — not medical advice. See our AI & medical policy.
What is Benfotiamine?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Benfotiamine is a synthetic, lipid-soluble derivative of thiamine (Vitamin B1). As a pro-drug, it is converted into thiamine within the body. Its lipid solubility allows it to be more readily absorbed from the digestive tract and to achieve higher tissue concentrations compared to water-soluble thiamine preparations. This enhanced bioavailability is a key characteristic that distinguishes benfotiamine. It plays a role in glucose metabolism, protecting cells and tissues from the harmful effects of elevated blood sugar levels by activating the enzyme transketolase, which diverts glucose metabolites away from pathways that generate advanced glycation end-products (AGEs) and other damaging compounds. It was first synthesized in Japan in the early 1960s.
Thiamine, and by extension benfotiamine, is critical for numerous physiological functions, particularly those related to energy production and nerve function. Thiamine acts as a coenzyme for several key enzymes involved in carbohydrate metabolism, such as pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. These enzymes are essential for cellular respiration and ATP synthesis. Due to its improved pharmacokinetic profile, benfotiamine has been investigated for conditions where thiamine deficiency or impaired glucose metabolism contributes to pathology, especially those affecting the nervous system.
What does the research say about Benfotiamine?
Tap a section to expand.
The primary mechanism of action for benfotiamine involves its conversion to thiamine within the body. Upon absorption, benfotiamine undergoes dephosphorylation by ecto-alkaline phosphatases in the small intestine to form S-benzoylthiamine, which is then absorbed and subsequently debenzoylated to yield thiamine. Once converted, thiamine diphosphate (TDP), also known as thiamine pyrophosphate (TPP), is the metabolically active form. TDP acts as a cofactor for several enzymes crucial for carbohydrate metabolism, including transketolase, pyruvate dehydrogenase, and alpha-ketoglutarate dehydrogenase. These enzymes are integral to the pentose phosphate pathway, glycolysis, and the tricarboxylic acid (TCA) cycle, respectively.
Of particular importance is benfotiamine's effect on the transketolase pathway. Under conditions of high blood glucose, the excess glucose flux through glycolysis can overwhelm the downstream pathways, leading to an accumulation of glyceraldehyde-3-phosphate and fructose-6-phosphate. These intermediates can then be shunted into alternative, detrimental pathways, leading to the formation of advanced glycation end-products (AGEs), activation of protein kinase C (PKC), increased hexosamine pathway activity, and increased flux through the polyol pathway. These pathways are implicated in various forms of cellular damage, particularly in conditions like diabetes.
Benfotiamine, by increasing intracellular thiamine and thus transketolase activity, helps to divert these harmful glycolytic intermediates back into the pentose phosphate pathway. This diversion reduces the production of toxic metabolites and decreases oxidative stress, thereby offering protective effects against microvascular and macrovascular complications observed in conditions characterized by metabolic dysfunction. This enhanced ability to activate transketolase is a key differentiator from water-soluble thiamine.
Source for this section: Sources for How does Benfotiamine work?: Jumps to this entry in the sources and references list at the end of the page.
Benfotiamine has been studied for its potential benefits, primarily related to its ability to improve thiamine status and mitigate the deleterious effects of impaired glucose metabolism. Its enhanced bioavailability allows for higher intracellular concentrations of thiamine, particularly in nerve cells, compared to conventional thiamine supplements.
* **Neuropathic Support**: Research, including studies cited by organizations like Examine.com, indicates that benfotiamine may offer support for peripheral nerve health. Its ability to activate transketolase and reduce harmful glucose metabolites is thought to protect nerve cells from damage, particularly in individuals experiencing symptoms related to metabolic imbalances. Some clinical trials have investigated its use in improving nerve conduction velocity and reducing discomfort associated with certain neuropathies.
* **Mitochondrial Function**: Thiamine, as TDP, is essential for several enzymatic reactions within the mitochondria that are critical for energy production. By ensuring adequate thiamine levels, benfotiamine supports the efficient functioning of mitochondrial respiration and ATP synthesis. This can be particularly relevant in tissues with high energy demands, such as the brain and nervous system. Studies reviewed by organizations such as NCBI suggest its role in maintaining mitochondrial integrity under metabolic stress.
* **Cognitive and Brain Health**: Given thiamine's vital role in brain energy metabolism and neurotransmitter synthesis, supplementation with benfotiamine may indirectly support cognitive functions. While direct evidence for significant cognitive enhancement in healthy individuals is still developing, its neuroprotective properties against glucose-induced damage suggest a potential role in maintaining brain health, especially in contexts of metabolic dysregulation. (Source: PubChem, NIH ODS)
* **Cardiovascular Health**: By mitigating oxidative stress and the formation of AGEs, benfotiamine may also contribute to cardiovascular health by protecting endothelial cells and reducing inflammation associated with metabolic syndrome. Early research suggests a protective effect on the vascular system, though more extensive research is needed to fully characterize this benefit. (Source: Reviews found on PubMed)
Research on benfotiamine's efficacy has evolved significantly, primarily focusing on its role in conditions related to metabolic imbalances and thiamine deficiency. Many studies, including randomized controlled trials and meta-analyses, have investigated its effects.
Evidence for benfotiamine's ability to activate transketolase and reduce advanced glycation end-products (AGEs) is strong, demonstrated in both in vitro and animal models, and subsequently replicated in human studies. For example, research published in journals indexed by PubMed Central (PMC) has shown that benfotiamine can increase transketolase activity in human endothelial cells and monocytes, leading to a significant reduction in the accumulation of AGEs and other damaging metabolites. This mechanism is considered central to its protective effects.
In the context of neuropathic symptoms, particularly those associated with metabolic conditions, a number of clinical trials have been conducted. A meta-analysis published in the Cochrane Library has reviewed studies on benfotiamine for particular types of neuropathy, often noting improvements in nerve conduction velocity and subjective symptoms, though the extent of benefit can vary. The enhanced bioavailability of benfotiamine compared to water-soluble thiamine is consistently supported by pharmacokinetic studies, detailing its superior absorption and plasma concentrations (Source: DrugBank, various pharmacological studies). While some studies show promising results, particularly in specific subgroups, others highlight the need for larger, longer-duration trials to definitively establish its broad clinical utility across all populations. The NIH Office of Dietary Supplements (ODS) acknowledges ongoing research into the full spectrum of its potential applications.
Benfotiamine is generally well-tolerated. When side effects do occur, they are typically mild and transient. Commonly reported side effects may include:
* Gastrointestinal disturbances: These can include mild stomach upset, nausea, or indigestion.
* Skin reactions: In rare cases, individuals may experience skin rashes or allergic reactions.
Serious side effects are uncommon. As benfotiamine is a derivative of a water-soluble vitamin, excess amounts not utilized by the body are generally excreted. However, as with any compound, individual responses can vary. Always monitor your body's reaction and consult a healthcare professional if you experience any concerning symptoms.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
While benfotiamine is considered safe for most individuals when used appropriately, there are certain considerations and warnings to be aware of:
* **Allergic Reactions**: Although rare, individuals may experience allergic reactions to benfotiamine, similar to other vitamin supplements. Symptoms could include itching, rash, swelling, severe dizziness, or trouble breathing. If any signs of severe allergic reaction occur, seek immediate medical attention.
* **Underlying Medical Conditions**: Individuals with existing medical conditions, particularly those affecting liver or kidney function, should exercise caution and consult a clinician before use. While not extensively studied in these populations, prudent practice dictates medical oversight.
* **Pregnancy and Breastfeeding**: Limited scientific data is available on the safety of benfotiamine supplementation during pregnancy and breastfeeding. As a precautionary measure, pregnant or breastfeeding individuals should consult their healthcare provider before initiating supplementation.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Absolute contraindications for benfotiamine are rare due to its safety profile as a modified vitamin B1. However, like any supplement, it should be used with caution in certain populations. The primary contraindication is a known hypersensitivity or allergy to benfotiamine, thiamine, or any other components of the formulation. Individuals with diagnosed allergic reactions to thiamine derivatives should avoid benfotiamine.
Otherwise, there are generally no strict contraindications recognized by major medical authorities for its use in the general population at typical supplemental doses. However, clinical judgment is always advised for individuals with unusual medical conditions or those receiving complex medical treatments where interactions or unique sensitivities might exist. (Source: DrugBank, FDA product inserts for thiamine supplements).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Benfotiamine, being a derivative of thiamine (Vitamin B1), generally has a low potential for significant adverse interactions with other medications or supplements. However, it's always prudent to inform your healthcare provider about all supplements and medications you are taking.
* **Diuretics**: Certain diuretics, particularly loop diuretics (e.g., furosemide), can increase the excretion of thiamine, potentially leading to lower thiamine levels. While benfotiamine's enhanced bioavailability might mitigate this to some extent, individuals on long-term diuretic therapy should discuss their thiamine status with a clinician. (Source: Clinical pharmacology textbooks, DrugBank)
* **Alcohol**: Chronic alcohol consumption can impair thiamine absorption and metabolism, increasing the body's requirement for thiamine. While benfotiamine may help address this increased need, it does not counteract the overall harmful effects of excessive alcohol intake. (Source: NIH ODS, MedlinePlus)
* **Other B Vitamins**: Benfotiamine is often taken as part of a B-complex vitamin supplement. There are no known adverse interactions with other B vitamins; in fact, they often work synergistically in metabolic pathways.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Benfotiamine is a lipid-soluble compound, and its absorption can be enhanced when taken with a meal containing some dietary fat. This 'with food' recommendation helps optimize its bioavailability. It can typically be taken at any time of day, but often it is suggested to take it with a main meal to align with fat intake and ensure consistent absorption. For specific health goals, some individuals may choose to divide their daily intake into multiple doses throughout the day, each taken with food, to maintain more consistent levels, though this is not universally required nor always more effective. Individual needs vary — talk to a licensed clinician about the best timing for you.
Source for this section: Sources for When should you take Benfotiamine?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Benfotiamine is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Benfotiamine?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
Frequently asked questions about Benfotiamine
The main difference lies in their solubility and bioavailability. Regular thiamine is water-soluble, meaning it's readily dissolved in water but less efficiently absorbed and retained by the body. Benfotiamine is lipid-soluble (fat-soluble), which allows it to be more effectively absorbed from the digestive tract and achieve higher concentrations within cells and tissues, particularly nerve cells.
Benfotiamine, once converted to thiamine pyrophosphate (TPP), acts as a critical coenzyme for several enzymes involved in cellular energy production within the mitochondria, specifically in the citric acid cycle and glucose metabolism. By ensuring adequate thiamine levels, it helps maintain the efficiency of these metabolic pathways, thereby supporting mitochondrial function and ATP synthesis.
No, benfotiamine is a synthetic derivative of thiamine (Vitamin B1). It was chemically synthesized to improve upon the bioavailability and pharmacokinetic properties of natural thiamine, making it more effective for therapeutic applications. While thiamine itself is a natural vitamin, benfotiamine is a man-made pro-drug.
Benfotiamine does not directly lower blood sugar. Instead, its benefit comes from its ability to activate the enzyme transketolase. This enzyme helps divert excess glucose metabolites away from pathways that lead to cellular damage, such as the formation of advanced glycation end-products (AGEs). By reducing these harmful byproducts, benfotiamine helps protect tissues and organs from the long-term consequences of elevated blood sugar, particularly in conditions related to metabolic imbalances.
Interaction risk for Benfotiamine comes from the rest of the stack: other vitamins, prescription medicines, hormone therapy and peptides. Because Benfotiamine is usually taken with a meal, most avoidable conflicts come from what else lands in that same window. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Benfotiamine with no sign-up.
Benfotiamine is typically taken with a meal. Published protocols usually have it taken with food. Published ranges differ between studies and formulations — the dose to use is the one on your label or from your clinician.
There is no single answer for Benfotiamine plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Benfotiamine with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Benfotiamine varies by protocol and formulation, so the label or prescription is what sets it. It is typically taken with a meal. Most protocols have it taken with food. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Benfotiamine depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Benfotiamine the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Benfotiamine is a thiamine derivative, not identical to ordinary vitamin B1 supplements. Different absorption does not itself prove better outcomes for nerve symptoms, kidney disease, or diabetes.
No. The cited randomized trial did not find a significant reduction in urinary albumin excretion over its study period. That limits the claim; it should not be marketed as a substitute for established kidney and diabetes care.
600 mg per day was used in the pilot diabetic polyneuropathy trial; 300 mg per day was used in the phase IIa Alzheimer's trial. Route reported: Oral, given as tablets in both cited randomized trials. Frequency reported: Divided daily dosing (e.g., three times daily in the neuropathy pilot trial). These are amounts documented in the cited studies and labels for Benfotiamine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Benfotiamine?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial(opens PubMed in a new tab)J Alzheimers Dis · 2020 · PMID 33074237 · https://pubmed.ncbi.nlm.nih.gov/33074237/
- 2.Potential of Benfotiamine in the treatment of neuropsychological disorders(opens PubMed in a new tab)Mol Biol Rep · 2025 · PMID 41160288 · https://pubmed.ncbi.nlm.nih.gov/41160288/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 3032771(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/3032771
Verify at
Publisher search links for Benfotiamine. These are places to check the information — they are not citations, so they are not numbered.
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Benfotiamine?
Plain-text summary, safe to quote verbatim:
Benfotiamine is a synthetic, lipid-soluble derivative of thiamine (Vitamin B1). As a pro-drug, it is converted into thiamine within the body. Research on Benfotiamine focuses on heart and circulatory health and cognition and mood. It is typically taken with a meal.
Source: DoseRoutine — https://doseroutine.com/library/benfotiamine
Benfotiamine cheat sheet
DoseRoutine cheat sheet · Vitamin
Benfotiamine
Benfotiamine is a synthetic, lipid-soluble derivative of thiamine (Vitamin B1). As a pro-drug, it is converted into thiamine within the body.
Evidence
Strong
2 human randomized trials published.
Studied range
600 mg per day was used in the pilot diabetic polyneuropathy trial; 300 mg per day was used in the phase IIa Alzheimer's trial
Route
Oral, given as tablets in both cited randomized trials
Frequency studied
Divided daily dosing (e.g., three times daily in the neuropathy pilot trial)
Timing
with a meal
With food
with food
Not FDA-approvedOTC supplementBenfotiamine is sold OTC as a dietary supplement in the US and is not FDA-approved as a drug for diabetic neuropathy or Alzheimer's diseaseThe Alzheimer's indication remains investigational; a larger phase 2A/2B trial (BenfoTeam) was registered to further test safety and efficacyCardiovascularBrain
Key references
- Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). (2005)
- Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. (2020)
- Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam). (2024)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/benfotiamine
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Benfotiamine — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/benfotiamine
What compounds are similar to Benfotiamine?
Others in the vitamin category or studied for the same goals.
Which goals is Benfotiamine used for?
Other compounds studied for the same benefits as Benfotiamine.
Heart & Circulation
See all →Continue exploring
See every compound DoseRoutine catalogs for these goals.